Technologies for iPSC differentiation into insulin-secreting β-cells have been applied to generate β-cells or endocrine tissue from patients suffering from different subtypes of diabetes, such as type I diabetes (T1D), type II diabetes (T2D), and monogenic diabetes (MD) (Table 4) [88,98,99,100]. This evidence concerns the gene INS and type 2 diabetes mellitus.